Towards a New Challenge in TB Control: Development of Antibody-Based Protection by Armando Acosta et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
18 
Towards a New Challenge in TB Control: 
Development of Antibody-Based Protection 
Armando Acosta1*, Yamile Lopez1,  
Norazmi Mohd Nor2, Rogelio Hernández Pando3,  
Nadine Alvarez1 and Maria Elena Sarmiento1 
1Instituto Finlay, La Habana,  
2School of Health Sciences, Universiti Sains Malaysia, Kelantan,  
 3Experimental Pathology Section, National Institute of Medical Sciences and Nutrition, 
Mexico City, 
1Cuba 
2Malaysia  
3Mexico 
1. Introduction 
Throughout history tuberculosis (TB) has been a health problem for humanity. In the 
beginning of civilization when human population densities were sparse, this disease may 
have been fairly harmless. However, with the increase in population densities, probably 
from the 17th to 19th centuries, TB took epidemic proportions [1]. 
Bacille Calmette Guérin (BCG), the only licensed vaccine against TB, has been shown to be 
effective in preventing meningeal and miliary TB in children. However, the efficacy of this 
vaccine in preventing adult pulmonary TB is questionable. Despite widespread vaccination 
with BCG, nearly 2 million people die each year from TB. Furthermore, the World Health 
Organization no longer recommends BCG vaccination of children with HIV or HIV-positive 
mothers due to safety concerns, leaving many infants without any protection against this 
disease. While drug therapies exist to combat TB infection, the implentation of suitable 
treatment is often difficult in the countries hardest hit by the disease and a fact complicated 
by the limited effectiveness of the current therapeutic schemes at treating drug resistant 
strains of TB [2-4]. 
Nowadays there is an increasing realization of the need of new animal models to test 
vaccine efficacy in more realistic scenarios overcoming the limitations of the current models 
in use. In addition, the elucidation of the significance of humoral defense against 
intracellular pathogens, in particular against Mycobacterium tuberculosis, constitutes an 
exciting new approach to improve the rational design of new vaccines, therapies and 
diagnostics. 
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2. Reshaping the classical paradigm 
In order to develop improved vaccines and new methods for the control of TB, an important 
element is the discovery of markers to measure the effector mechanisms of the protective 
immune response against M. tuberculosis. For many years Cellular Mediated Immunity 
(CMI) was attributed as the exclusive defence mechanism against intracellular pathogens. 
The Th1/Th2 classical paradigm prevailed for a long time and directed the development of 
vaccines according to this theory [5]. 
Based on this point of view, only intracellular pathogens could be effectively controlled by 
granulomatous inflammation induced by a Th1 response whereas a Th2 response induces 
antibody production that control extracellular pathogens and parasites. However, the 
question arises of what really constitutes the true demarcation between “extracellular and 
intracellular”? In the infectious cycle of several intracellular pathogens, they could be found 
in the extracellular space and vice versa. In the specific case of M. tuberculosis, it can be 
localized extracellularly at the beginning of the infection in the upper respiratory tract as 
well as in advanced stages of the disease after the rupture of granulomatous lesions [6]. In 
the case of Erhlichia spp specific antibodies could mediate protection against [7], possibly by 
blocking cellular entry or promoting the expression of proinflammatory cytokines [8;9]. It 
has been demonstrated that this obligate intracellular pathogen has also an extracellular 
phase that may include replication which could be targeted by specific antibodies [10]. 
For certain viral pathogens, the induction of Antibody Mediated-Immunity is sufficient to 
prevent infection, as has been clearly demonstrated by the almost complete eradication of 
smallpox with the use of vaccines that elicited antibody-mediated immunity [11]. There are 
several prokaryotic and eukaryotic intracellular pathogens for which antibody have been 
shown to modify the course of infection by different mechanisms, as reviewed extensively 
by Casadevall and colleagues [12-14]. Nowadays, it is well established that an efficient 
combination of both humoral and cellular immune mechanisms could be the best choice to 
control certain diseases produced by intracellular pathogens [15;16].  
In 2005, de Valiere and colleagues reported for the first time that human antimycobacterial 
antibodies stimulates the Th1 response instead of diminishing it, as was thought previously 
[17].  
3. Protective role of antibodies: Epidemiological evidence  
There is accummulated evidence in the last few decades on the influence of antibodies in the 
development of pulmonary or disseminated TB. Children with low serum IgG against 
sonicated mycobacterial antigens and LAM, or those who cannot mount antibody responses 
to these antigens, were predisposed to dissemination of the bacteria [18]. In another report, 
Kamble and colleagues reported that M. leprae reactive salivary IgA antibodies could be 
quite important in a mucosal protective immunity [19]. In one study carried out on the 
Mexican Totonaca Indian population, the presence of high antibody titers to Ag85 complex 
antigens were observed in patients with non-cavitary TB and in patients who were cured 
with anti-TB chemotherapy. In contrast, patients without such antibodies had a poor 
outcome of the disease [20]. 
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4. Experimental studies 
4.1 Animal models for the evaluation of the role of antibodies in TB infection 
One important criterion for the evaluation of the role of specific antibodies in the 
protection against TB is the use of animal models. Currently, there is no optimal model to 
reproduce the infection as it occurs in humans [21]. Several animal models have been used 
to evaluate different aspects. One crucial aspect is the delivery of inoculums, where 
several routes of inoculation have been employed as intravenous, intraperitoneal, 
intranasal, aerosol and intratracheal [22]. The geographical location, genetic factors of the 
host, the presence of environmental mycobacteria and other concomitant infections  
like helminthiasis, are factors that have to be considered when designing animal 
experiments [23]. 
The study of the distribution of monoclonal and polyclonal antibody formulations in 
different organs and tissues of mice after administration by different routes, including the 
use of backpack models have been reported [24-26]. Each model has its advantages and 
drawbacks. For example, the backpack model is very useful for the evaluation of the 
protective role of IgA, but poses ethical problems in long term experiments due to the 
increase in tumour size over time produced by the inoculated hybridoma [27]. 
In prophylactic and therapeutic models, antibody formulations have been administered via 
the intranasal, intravenous and intraperitoneal routes and combined with cytokines and 
antibiotics [28,29] before and/or after the infectious challenge. 
The administration of M. tuberculosis pre-coated with antibodies [30,31] in different models 
of infection have also contributed to understanding the interactions between host and 
microbe. 
Another approach has been the use of knockout mice models for IgA, polymeric 
immunoglobulin receptor (pIgR) and B cells, as will be discussed later. 
4.2 Experimental studies with antibodies  
A great number of studies involving antibodies as inoculum have been conducted as far 
back as the end of the 19th century. These experiments can be grouped in several categories: 
serum therapies, mouse polyclonal antibodies, human polyclonal antibodies including 
commercial human gamma globulins, secretory human IgA (hsIgA) and studies with 
monoclonal antibodies.  
4.2.1 Serum therapies 
Serum therapy experiments were conducted from the second half of the 19th century. 
Immune sera was generated by immunizing animals with different microbial fractions and 
administered either to animals or humans. The results obtained were either variable, 
inconclusive or contradictory, due to differences in the methods of serum preparation or its 
administration, and the lack of appropriate experimental controls [32]. These controversial 
results led to the perceived minor role of antibodies in the defence against intracellular 
pathogens.  
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Why these results were considered ¨controversial¨? Immune serum is a polyclonal 
preparation that includes antibodies to multiple specificities and isotypes; consequently, 
polyclonal sera may contain blocking antibodies [33] and antibodies of different functional 
categories that can affect the outcome of infection. For example, IgG3 murine monoclonal 
antibodies protects against Streptococcus pneumoniae and M. tuberculosis but fails to protect 
against C. neoformans [34]. Moreover, results from animal studies are not always reflective of 
the Ig isotype function in humans. Besides intrinsic factors associated to the antibody 
structure, other parameters such as the genetic background of the microbe and the 
immunocompetence of the host could alter the outcome of antibody protection experiments. 
For some microorganisms (Legionella pneumophila and C. neoformans), passive antibody 
therapy efficacy depends on the mouse strain used [35]. In the same way, some microbial 
strains are more susceptible to the effects of antibodies. The animal model used is another 
important parameter that varies between different experiments cited in the literature. 
Timing, the route of infection, the magnitude of the infecting inoculum and the variables to 
measure efficacy are some of the critical parameters in antibody protection studies [36]. 
Despite its controversial nature, the results obtained with serum therapy were valuable, 
demonstrating some beneficial effect of serum on the course of TB in humans, mainly in 
cases of early or localized TB [37]. Moreover, it was demonstrated that long periods of 
treatment were necessary to achieve a sustained effect [38]. 
4.2.2 Polyclonal mouse antibodies 
A recent study re-examined the usefulness of immune serum in the context of a therapeutic 
vaccine against TB [39]. This vaccine, called RUTI, is generated from detoxified  
M. tuberculosis cell fragments that facilitate a balanced T helper response to a wide range of 
antigens along with intense antibody production. Local accumulation of specific CD8+  
T cells and a strong humoral response after immunization are characteristic features of 
RUTI, features that contribute to its protective properties. In this study, immune serum was 
generated by immunizing mice with RUTI. Severe Combined Immunodeficiency (SCID) 
mice were infected with M. tuberculosis and treated with chemotherapy for 3–8 weeks. After 
chemotherapy they were treated for up to 10 weeks with intraperitoneal injections of 
immune serum. Mice treated with immune serum from RUTI vaccinated animals showed 
significant decreases in lung CFU as well as reduction in the extent of granulomatous 
response and abscess formation in comparisson with controls. These results suggest that 
protective serum antibodies can be elicited by vaccination, and that antibodies may be 
usefully combined with chemotherapy [29,40]. 
4.2.3 Human gammaglobulins 
4.2.3.1 Human polyclonal antibodies 
The first evidence of the stimulatory role upon cellular immunity of specific antibodies in 
experimental mycobacterial infections was reported by Valiere and colleagues in 2005. In 
this study, serum samples containing specific antimycobacterial antibodies were obtained 
from volunteers vaccinated twice with BCG by the intradermal route. Significant titres of 
IgG antibodies against lipoarabinomannan (LAM) were detected in the volunteers. 
Moreover, BCG internalization into phagocytic cells was significantly increased in the 
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presence of BCG induced antibodies as were the inhibitory effects of neutrophils and 
macrophages on mycobacterial growth. Furthermore, these antibodies induced significant 
production of IFN-Ǆ by CD4+ and CD8+ T cells [17]. 
4.2.3.2 IgG formulations 
Roy and colleagues demonstrated that the treatment of M. tuberculosis-infected mice with a 
single cycle of human intravenous Ig resulted in substantially reduced bacterial loads in the 
spleen and lungs when administered either at early or at late stage of infection [41]. 
The effect of the administration of a commercial preparation of human gammaglobulins in a 
mouse model of intranasal infection with BCG was evaluated by our group. We 
demonstrated the passage of specific antibodies to saliva and lung lavage following the 
intranasal or intraperitoneal administration of human gammaglobulins to mice. This 
treatment inhibited BCG colonization of the lungs of treated mice. A similar inhibitory effect 
was observed after infection of mice with gammaglobulin-opsonized BCG [42]. The same 
formulation was evaluated also in a mouse model of intratracheal infection with M. 
tuberculosis. Animals receiving human gammaglobulins intranasally 2h before intratracheal 
challenge showed a significant decrease in lung bacilli load compared to non-treated 
animals. When M. tuberculosis was pre-incubated with the gammaglobulin before challenge 
the same effect was observed. The protective effect of the gammaglobulin formulation was 
abolished after pre-incubation with M. tuberculosis [30]. These results suggest a potential role 
of specific human antibodies in the defence against mycobacterial infections. 
Taken together these studies provide consistent support for the potential use of 
gammaglobulins and their beneficial immunomodulatory effects in tuberculosis. The results 
of certain knockout mouse studies and the gammaglobulin experiments indicate that B cells 
and their products mediate protection against M. tuberculosis [43-45]. However, the 
important question that remains is whether B-cell responses can be augmented to improve 
immunity against M. tuberculosis through immunotherapy or vaccination. 
4.2.3.3 Purified human secretory IgA 
Human secretory IgA (hsIgA) is the major class of antibody associated with immune 
protection of the mucosal surfaces [46]. Colostrum volume is above 100 mL in humans 
during the first three days after delivery [47]. The high percentage of (hsIgA) in human 
colostrum [48] strongly suggests its important role in passive immune protection against 
gastrointestinal and respiratory infections [49]. In one study performed by our group, hsIgA 
from human colostrum was obtained by anion exchange and gel filtration chromatographic 
methods, using DEAE Sepharose FF and Superose 6 preparative grade, respectively [50]. 
HsIgA was administered intranasally to BALB/c mice, and the level of this immunoglobulin 
in several biological fluids was determined by ELISA. The results showed the presence of 
this antibody in the saliva of animals that received the hsIgA, at all time intervals studied. In 
tracheobronchial lavage, hsIgA was detected at 2 and 3 hours after inoculation in animals 
that received the hsIgA [51]. Similar studies were performed by Falero and colleagues with 
monoclonal antibodies of IgA and IgG class [52]. Following demostration that hsIgA could 
be detected in several biological secretions after intranasal administration, the protective 
effect of this formulation against M. tuberculosis challenge was evaluated. Mice challenged 
with M. tuberculosis preincubated with hsIgA showed a statistically significant decrease in 
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the mean number of viable bacteria recovered from the lungs compared to control mice and 
to the group that received the hsIgA before challenge with M. tuberculosis. Moreover, an 
increased level of iNOS production was also reported (Alvarez et al., mannuscript in 
preparation). Consistently with this result, a better organization of granulomatous areas 
with foci of lymphocytes and abundant activated macrophages were observed in the lungs 
of mice of the group that received M. tuberculosis pre-incubated with hsIgA sacrificed at 2 
months post-challenge. Untreated animals, however, showed an increased area of 
bronchiectasis and atelectasis as well as fibrin deposits, accumulation of activated 
macrophages and lymphocytes. The pneumonic areas were more prominent in the 
untreated animals than in the groups treated with hsIgA and M. tuberculosis pre-incubated 
with hsIgA (Alvarez et al., mannuscript in preparation) 
4.2.4 Studies performed with monoclonal antibodies 
Since the first report on the use of the monoclonal antibody Mab 9d8 against M. tuberculosis, 
many similar studies have been reported [53;54]. This IgG3 monoclonal antibody (Mab) 
generated against arabinomannan (AM) capsular polysaccharide, increased thesurvival of 
intratracheally infected mice when the M. tuberculosis Erdman strain was pre-coated with it. 
In this study, a longer survival associated with an enhanced granulomatous response in the 
lungs was found as compared to controls receiving an isotype-specific non-related Mab [31].  
Another Mab, SMITB14, directed against the AM portion of LAM prolonged the survival of 
intravenously infected mice associated with reduced lung CFU and prevention of weight loss. 
In this study, the authors demonstrated that protection was independent of the antibody Fc 
portion, because the F(ab’)2 fragment also conferred a similar protective effect [55]. 
In another study, mice receiving the Mab 5c11 (an IgM antibody that recognizes other 
mycobacterial arabinose-containing carbohydrates in addition to AM) intravenously prior to 
Mannosylated lipoarabinomannan (ManLAM) administration, showed a significant 
clearance of ManLAM and redirection of this product to the hepatobiliary system. This 
study strongly supports an indirect effect of certain antibodies on the course of 
mycobacterial infection, altering problably the pharmacokinetics of mycobacterial 
components and contributing to protection against TB [56]. 
Heparin Binding Hemagglutinin Adhesin (HBHA) is a surface-exposed glycoprotein 
involved in the mycobacterial binding to epithelial cells and in mycobacterial dissemination 
[57]. Monoclonal antibodies 3921E4 (IgG2a) and 4057D2 (IgG3) directed against HBHA were 
used to coat mycobacteria before administration to mice. In this study, spleen CFUs were 
reduced while lung CFUs did not [58]. These results suggest that binding of these antibodies 
to HBHA impede mycobacterial dissemination. 
The protective efficacy of a monoclonal antibody, TBA61, IgA anti-Acr administered 
intranasally before and after the intranasal or aerosol challenge with M. tuberculosis was 
demonstrated in a previous work [59]. In another series of experiments carried out by López 
and colleagues, the protective effect of this Mab administered intratracheally before an 
intratracheal challenge with virulent mycobacteria was evaluated. At 21 days post-infection, 
pre-treatment of mice with TBA61 caused a significant decrease in viable bacteria in the 
lungs compared to control mice or those treated with the Mab against the 38-kDa protein 
(TBA84). Consistent with the reduction of viable bacteria following treatment with TBA61, 
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the area of peribronchial inflammation was also statistically smaller in this group compared 
to the control group [60].  
When the lungs of mice were histologically examined, granulomas were better organized in 
the infected animals that had received TBA61 than in controls or mice treated with TBA84. 
The reduction of CFU in lungs of the treated group was associated with milder 
histopathological changes, as indicated by the organization of the granulomas and less 
pneumonic area. The fact that this Mab promotes granuloma formation in mice infected 
intratracheally with M. tuberculosis strongly suggests the close interaction between antibody-
mediated immunity and cell-mediated immunity to induce protection against intracellular 
pathogens (61). Some of the results obtained in the evaluation of TBA61 monoclonal 
antibody under different conditions are listed in the Table 1. 
 
MAb, delivery 
route and 
inoculation 
regime 
Challenge
Days 
selected for 
Organ 
Harvesting 
Parameter measured References 
CFU 
reduction 
Histopathology  
TBA61 i.n  
(-3h, +3h, 6h) 
TBA61 i.n (-3h) 
TBA61 i.n (+3h) 
TBA61 i.n 
 (-3h, +3h) 
H37Rv i.n, 
aerosol 
9 days 
Significant 
reduction of
CFU post-
challenge 
nd 59 
TBA61 i.n + IFN-Ǆ 
i.n 
(-3h, -2h, +2h, 
+7h) 
H37Rv 
i.n, aerosol
9, 21 and 
28 days 
Significant 
reduction of
CFU post-
challenge 
Significant 
reduction of the
granulomatous
area in the  
lungs of 
treated as, 
compared to 
untreated mice 
28 
TBA61 i.t (-3h) 
H37Rv 
i.t 
24h, 72h, 
21 days 
Significant 
reduction at 
21 days post-
challenge 
Less interstitial 
and 
peribronchial 
inflammation. 
Well-organized 
granuloma 
60 
Table 1. Results from different experimental approaches involving a monoclonal antibody 
against M. tuberculosis 16 kDa protein (TBA61). Note: i.n: intranasal; i.t: intratracheal 
The 16 kDa protein (Acr antigen) has been defined as a major membrane protein 
peripherally associated with the membrane [62] carrying epitopes restricted to tubercle 
bacilli on the basis of B-cell recognition [63,64]. The Acr antigen is present on the surface of 
tubercle bacilli and is highly expressed in organisms growing within infected macrophages, 
allowing it to be potentially targeted by specific antibodies either inside infected cells as well 
as extracellulary.  
www.intechopen.com
 
Understanding Tuberculosis – Analyzing the Origin of Mycobacterium Tuberculosis Pathogenicity 
 
422 
A novel immunotherapy, combining treatment with anti-IL-4 antibodies, IgA antibody 
against 16 kDa protein and IFN-, showed the potential for passive immunoprophylaxis 
against TB. In genetically deficient IL-4-/- BALB/c mice, infection in both lungs and spleen 
was substantially reduced for up to 8 weeks. Reconstitution of IL-4-/- mice with rIL-4 
increased bacterial counts to wild-type levels and making mice refractory to protection by 
IgA/IFN- [65]. 
More recently, Balu and colleagues reported a novel human IgA1 Mab, constructed using a 
single-chain variable fragment clone selected from an Ab phage library. The purified Mab 
monomer revealed high binding affinities for the mycobacterial ǂ-crystallin Ag and for the 
human FcǂRI (CD89) IgA receptor. Intranasal inoculations with the monoclonal antibody 
and recombinant mouse IFN-Ǆ significantly inhibited pulmonary H37Rv infection in mice 
transgenic for human CD89 but not in CD89-negative littermate controls, suggesting that 
binding to CD89 was necessary for the IgA-imparted passive protection. The Mab added to 
human whole-blood or monocyte cultures inhibited luciferase-tagged H37Rv infection 
although not for all tested blood donors. Inhibition of the infection by the antibody was 
synergistic with human rIFN-Ǆ in cultures of purified human monocytes but not in whole-
blood cultures. The demonstration of the mandatory role of FcǂRI (CD89) for human IgA-
mediated protection is important for understanding the mechanisms involved and also for 
translating this approach towards the development of passive immunotherapy for TB [66]. 
In all the studies analyzed, it is possible to assert that different mechanisms of action of 
monoclonal and polyclonal antibodies are involved in the protection against TB. Some of 
these mechanisms will be discussed later in this chapter.  
4.2.5 Studies performed in transgenic mice 
Mouse models with deficiency in antibody production can be useful in understanding 
certain roles of the antibodies in protection against mycobacterial infections. However, 
knockout mouse studies can lead to premature conclusions regarding the role of a particular 
component of immunity, if not interpreted carefully. Additionally, experimental conditions 
can have marked effects on the results. 
Rodríguez and colleagues reported that IgA deficient (IgA-/-) mice and wild type non-
targeted littermate (IgA+/+) were immunized by intranasal route with the mycobacterium 
surface antigen PstS-1. These authors showed that IgA-/- mice were more susceptible to 
BCG infection compared to IgA+/+ mice, as revealed by the higher bacterial loads in the 
lungs and bronchoalveolar lavage (BAL). More importantly, analysis of the cytokine 
responses revealed a reduction in the IFN-and TNF- production in the lungs of IgA-/- 
compared to IgA+/+ mice, suggesting that IgA may play a role in protection against 
mycobacterial infections in the respiratory tract. Furthermore, these authors demonstrated 
that immunized pIgR-/- mice were more susceptible to BCG infection than immunized 
wild-type mice [67]. 
In the attempt to elucidate whether humoral immunity has a special role in the defence 
against TB, different experiments with B cell knockout mice were performed by several 
authors. In 1996, Vordermeier and colleagues developed an infection model of TB in μ chain 
knockout Ig- mice. Organs from M. tuberculosis infected IgG- mice had three to eight fold 
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elevated counts of viable bacilli compared with those from normal mice. This result 
suggested that B cells play a role in the containment of murine tuberculous infection [68]. In 
another study, B cell gene disrupted mice (B cell KO) and controls were infected by aerosol 
with M. tuberculosis to allow the latter group to generate an antibody response in the upper 
respiratory tract. They were subsequetly given chemotherapy to destroy remaining bacilli 
and then re-challenged by aerosol exposure. The results of this study, however, revealed no 
differences in the ability of animals to control this second infection, indicating that, in this 
low dose pulmonary infection model at least, any local production of antibodies neither 
impeded nor enhanced the expression of specific acquired resistance [69].  
In another series of experiments the role of B cells during early immune responses to 
infection with a clinical isolate of M. tuberculosis (CDC 1551) was evaluated. In this study, 
despite comparable bacterial loads in the lungs, less severe pulmonary granuloma formation 
and delayed dissemination of bacteria from lungs to peripheral organs were observed in 
BKO mice. Additional analysis of lung cell populations revealed greater numbers of 
lymphocytes, especially CD8+ T cells, macrophages, and neutrophils in wild-type and 
reconstituted mice than in BKO mice. Thus, less severe lesion formation and delayed 
dissemination of bacteria found in BKO mice were dependent on B cells, (not antibodies, at 
least in this study) and were associated with altered cellular infiltrate to the lungs [70].  
This latter result differs to the study carried out by Maglione and colleagues in which  
B cell-/- mice had exacerbated immunopathology corresponding with elevated pulmonary 
recruitment of neutrophils upon aerosol challenge with M. tuberculosis Erdman strain. 
Infected B cell-/- mice showed increased production of IL-10 in the lungs, whereas IFN-, 
TNF-, and IL-10R remain unchanged from wild type. B cell-/- mice had enhanced 
susceptibility to infection when aerogenically challenged with 300 CFU of M. tuberculosis 
corresponding with elevated bacterial burden in the lungs but not in the spleen or liver [43]. 
Together these studies reveal that B cells may have a greater role in the host defence against 
M. tuberculosis than previously thought. 
5. Possible mechanisms of action 
Secretions found on mucosal surfaces contain significant levels of Igs, particularly, IgA. This 
immunoglobin has direct and indirect functional roles to combat infectious agents such as 
viruses and bacteria that cross the mucosal barrier. Moreover, experimental evidences 
suggest that the IgA associated with the pIgR may neutralize pathogens and antigens 
intracellularly during their transport from the basolateral to the apical zone of epithelial 
cells [71,72]. In addition, as demonstrated previously, IgA may interact with Gal-3 (an 
intracellular binding ǃ-galactosidase lectin), and interfere with the interaction of 
mycobacteria with the phagosomal membrane, resulting in the decrease of bacterial survival 
and replication in the phagosome [73].  
As reported by several authors, antibodies may be critical, at least during the extracellular 
phases of intracellular facultative pathogens. Antibodies may act by interfering with adhesion, 
neutralizing toxins and activating complement. Moreover, antibodies may be able to penetrate 
recently infected cells and bind to the internalised pathogen, increasing the antigen processing 
(74). It is well accepted that antibodies play a crucial role in modulating the immune response 
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by activating faster secretion of selected cytokines that in turn, contribute to more efficient and 
rapid Th1 response [74,75], increasing the efficacy of co-stimulatory signals, enhancing 
Antibody Dependent Cellular Cytotoxicity responses (ADCC) and the homing of immune 
cells to the lungs after the respiratory infection [13,76-81]. 
Examples of relevant action mechanisms of antibodies have been discussed by Glatman-
Freedman [82].  
6. Potential applications 
Future applications of antibody formulations for the control of TB may include treatment of 
patients infected with Multidrug Resistant (MDR) strains, combination with the standard 
treatment in order to achieve faster therapeutic effects, and administration to recent contacts 
of TB patients with special attention to risk groups [85]. 
On the other hand, the induction of specific antibody responses by vaccination in addition 
to the stimulation of cell mediated immunity could be a novel strategy for the development 
of new generation prophylactic and therapeutic vaccines against TB. 
The prevailing dogma about the uncertain role of antibodies in the protection against TB has 
somewhat limited the study of B cell immunodominant epitopes which have been mainly 
related with the development of serodiagnosis assays [86]. Consequently, little information 
is available on B cell epitopes that could potentially contribute to protection or therapy. 
With the development of bioinformatics tools for bacterial genome analysis, it has been 
possible to predict in silico microbial regions that trigger immune responses relevant for 
protection and vaccine development.  
Our group is currently developing a candidate experimental vaccine based on 
proteoliposomes from M. smegmatis. In one study, bibliographic search was used to identify 
highly expressed proteins in active, latent and reactivation phases of TB [87]. The subcellular 
localization of the selected proteins was defined according to the report on the identification 
and localization of 1044 M. tuberculosis proteins using two-dimensional, capillary high-
performance liquid chromatography coupled with mass spectrometry (2DLC/MS) method 
[88] and using prediction algorithms. 
Taking into consideration the cell fractions potentially included in the proteoliposome, from 
the previously identified proteins, the ones located in the cell membrane and cell wall, as 
well as those which are secreted and homologous to those of M. smegmatis were selected. 
The regions of the selected proteins containing promiscuous B and T cell epitopes were 
determined [87]. Thus the M. smegmatis proteolipomes were predicted to contain multiple  
B and T epitopes which are potentially cross reactive with those of M. tuberculosis. It is 
important to note that there could be conformational B epitopes and additional epitopes 
related with lipids and carbohydrates included in the proteoliposomes that could reinforce 
the humoral cross reactivity. 
Considering the results of the in silico analysis, proteoliposomes of M. smegmatis were 
obtained and their immunogenicity was studied in mice [89]. In addition to cellular immune 
effectors recognizing antigens from M. tuberculosis, cross reactive humoral immune 
responses of several IgG subclasses corresponding with a combined Th1 and Th2 pattern 
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against antigenic components of M. tuberculosis were elicited. These findings were in 
concordance with the in silico predictions [87,89]. It is interesting to note that differences in 
the pattern of humoral recognition of lipidic components was dependent on the 
characteristics of the adjuvant used, which could have relevance for the development of 
vaccines which includes lipidic components [89]. Currently studies are underway to 
evaluate the protective capacity of M. smegmatis proteoliposomes in challenge models with 
M. tuberculosis in mice.  
Bioinformatics tools for prediction of T and B epitopes were also employed for the design of 
multiepitopic constructions, which were used to obtain recombinant BCG strains. Based on 
this prediction, B cell epitopes from ESAT-6, CFP-10, Ag85B and MTP40 proteins were 
selected and combined with T cell epitopes of the 85B protein and fused to 8.4 protein [90]. 
A significant IgG antibody response against specific B cell epitopes of ESAT-6 and CFP-10 
was obtained in mice immunized with the recombinant strain. After studying the specific 
response of spleen cells by lymphoproliferation assay and detection of intracellular 
cytokines in CD4 + and CD8 + subpopulations, the recognition of T epitopes was also 
observed. The response showed a Th1 pattern after immunization with this recombinant 
strain (Mohamud, R, et al. manuscript in preparation). In another series of experiments, 
recombinant BCG strains expressing several combinations of multiepitopic constructions 
were used to immunize BALB/c mice subcutaneously and challenged intratracheally with 
the M. tuberculosis H37Rv strain. Recombinant BCG strains expressing T epitopes from 
85BAg fused to Mtb8.4 protein and BCG expressing a HSP60 T cell epitope plus different 
combinations of B cell epitopes from 85BAg, Mce1A, L7/L12, 16 kDa, HBHA, ESAT6, CFP10 
and MTP40 and combinations of B cell epitopes alone produced significant reductions in 
lung CFU compared with BCG (Norazmi MN, manuscript in preparation).  
The cumulative works reviewed above related with the use of antibody formulations and 
vaccines suggest that antibodies if present at the right moment at the site of infection can 
provide protection against M. tuberculosis. This concept opens the way to the development 
of a new generation of vaccines that elicit specific IgA and/or IgG antibodies able to protect 
at the port of entry against the infection and directed to bacteria in the infected tissues. 
An antibody-based vaccine could be implemented against TB. Such antibodies should 
recognize the pathogen immediately after its entry into the host, mainly at the mucosal 
surfaces, where these antibodies must be strategically induced [91]. This vaccine has to 
induce IgA and IgG antibodies that can inactivate bacterial components essential for the 
microbial survival in the host, activate complement for direct lysis of the cells, opsonize 
bacteria to promote their capture by phagocytic cells and induce stimulation of specific 
cellular immune responses. 
Although no serological tests for diagnosis of TB are recommended [92], due to the 
generation of false results as well as incorrect treatments, for many other pathogens, the 
availability of serological diagnostic tests has been of great value, in particular in poor 
countries. In some cases, it constitutes the best protection correlate [93].  
In the specific case of TB, several studies of the antibody response have been developed [94]. 
A number of factors have been described to contribute to the variation of antibody response 
during the disease. Some of these factors are associated to the pathogen (strain variation, 
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micro-environment and growth state of bacteria). Not less important are the factors related 
to the host, mainly the previous exposure to antigen and host genetics [95].  
On the other hand, only a small fraction of the genomic regions of M. tuberculosis encoding 
proteins has been explored. Currently, novel immunoassay platforms are being used to 
dissect the entire proteome of M. tuberculosis, including reacting protein microarrays with 
sera from TB patients and controls [96,97]. These studies could lead to the discovery of new 
antigens that may constitute a suitable diagnostic marker as well as to the identification of 
correlates of protection. 
The study of the role of specific antibodies in the defense against tuberculosis is opening 
new possibilities for the future development of new vaccines, diagnostics and therapies 
against the disease. It is envisaged that new discoveries will arise from the ongoing studies 
in this area that will expedite the introduction of new strategies in the fight against 
tuberculosis. 
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